Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer

NCT01977235 | Unknown Phase 2 DMC

• 1 other identifier: TDICC
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 3

Brief Summary

As the gene polymorphism of uridine diphosphate glucuronosyl transferase 1A1(UGT1A1)is related to the side effect of diarrhea induced by irinotecan. UGT1A1 gene \*28 (6/6 and 6/7) and \*6 (G/G and G/A) is related to low probability of diarrhea and UGT1A1 gene \*28 (7/7) and \*6 (A/A)is related to high probability of diarrhea. The purpose of this study is to find out the efficacy and side effect between two different dosages of irinotecan combined with cisplatin scheme in extensive disease-small cell lung cancer with UGT1A1 gene \*28 (6/6 and 6/7)and \*6 (G/G and G/A), based on the hypothesis that the UGT1A1 gene \*28 (7/7) and \*6 (A/A)is few in the Chinese population and increasing the dose of irinotecan can improve the efficacy without increasing the side effect in the patients with UGT1A1 gene \*28 (6/6 and 6/7)\*6 (G/G and G/A).

Conditions

Small Cell Lung Carcinoma

Keywords

Irinotecan; Cisplatin; Small-cell lung cancer; UGT1A1

Outcome Measures

Primary Outcomes (1)

• progression-free survival

  The first day of treatment to the date that disease progression is reported; assessed up to 3 years

Secondary Outcomes (4)

• overall survival

  the first day of treatment to death or last survival confirm date; assesed up to 3 years

• Tumor response rate

  Up to 3 years

• Toxicity

  the first date of treatment to 30 days after the last dose of study drug

• Quality of life

  the day before every cycle of chemotherapy; 30 days after the last dose of study drug

Study Arms (2)

Arm A

EXPERIMENTAL

Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.

Drug: Irinotecan; Drug: Cisplatin

Arm B

ACTIVE COMPARATOR

Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.

Drug: Irinotecan; Drug: Cisplatin

Interventions

Irinotecan DRUG

Arm A; Arm B

Cisplatin DRUG

Arm A; Arm B

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologic or cytologic diagnosis of small-cell lung cancer
• Extensive-stage disease, defined as disease extending beyond one hemithorax involving contralateral mediastinal, hilar or supraclavicular lymph nodes, and/or pleural effusion.
• Males or females between 18 to 75 years
• No prior chemotherapy, if the surgery or radiotherapy has been administered, the interval is at least above four weeks.
• Performance status of 0-2 on the ECOG criteria. Expected survival is above three months.
• At least one unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST. 2000).
• Patient compliance that allow adequate follow-up. Informed consent from patient or patient's relative.
• Adequate hematologic (neutrophil count \>= 1,500/uL, platelets \>= 100,000/uL), hepatic (transaminase =\< upper normal limit(UNL)x2.5, bilirubin level =\< UNL x 1.5), and renal (creatinine =\< UNL) function
• The gene type of UGT1A1 \*28 is 6/6 and 6/7.
• If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[IUD\], birth control pills, or barrier device) during and for 3 months after trial. If male, use of an approved contraceptive method during the study and 3 months afterwards. Females with childbearing potential must have a urine negative HCG test within 7 days prior to the study enrollment.
• No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital, phenytoin, ketoconazole.

You may not qualify if:

• Non small cell lung cancer and carcinoid
• Medically uncontrolled severe diarrhea in recent three weeks.
• Inability to comply with protocol or study procedures.
• Medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease
• Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
• Pregnant or breast-feeding.
• Enrollment in other study within 30 days
• Brain metastasis with symptoms

Sponsors & Collaborators

• Third Military Medical University: lead

Study Sites (3)

Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, China

RECRUITING

Xinan Hospital, Third Military Medical University

Chongqing, Chongqing Municipality, China

RECRUITING

Xinqiao Hospital, Third Military Medical University

Chongqing, Chongqing Municipality, China

RECRUITING

Related Publications (4)

• Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43. doi: 10.1200/JCO.2005.04.8595.

  PMID: 16648503 BACKGROUND

• Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.

  PMID: 23686699 BACKGROUND

• Zhang X, Meng X, Wang Y, Yan W, Yang J. Comprehensive analysis of UGT1A1 genetic polymorphisms in Chinese Tibetan and Han populations. Biochem Genet. 2012 Dec;50(11-12):967-77. doi: 10.1007/s10528-012-9536-y. Epub 2012 Sep 16.

  PMID: 22983686 BACKGROUND

• Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91. doi: 10.1056/NEJMoa003034.

  PMID: 11784874 BACKGROUND

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Interventions

Irinotecan; Cisplatin

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Camptothecin; Alkaloids; Heterocyclic Compounds; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Study Officials

• Xueqin Yang, M.D.

  Daping Hospital, Third Military Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xueqin Yang, M.D.

CONTACT

+86-023-68757158; yangxueqin@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: associate chief physician

Study Record Dates

• First Submitted: October 15, 2013
• First Posted: November 6, 2013
• Study Start: September 1, 2013
• Primary Completion: February 1, 2017
• Study Completion: September 1, 2017
• Last Updated: April 1, 2016

Record last verified: 2016-03

Locations

CN (3)